Is Acutus Medical (AFIB) a Smart Long-term Buy?

Baron Discovery Fund recently published its third-quarter commentary – a copy of which can be downloaded here. During the third quarter of 2020, the Baron Discovery Fund returned 18.83% (institutional shares). This was 11.67% better than the Russell 2000 Growth Index, the Fund’s primary benchmark index. You should check out Baron Discovery Fund’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.

In the Q3 2020 Investor Letter, Baron Discovery Fund highlighted a few stocks and Acutus Medical Inc. (NASDAQ:AFIB) is one of them. Acutus Medical Inc. (NASDAQ:AFIB) develops and produces medical products. In the last three months, Acutus Medical Inc. (NASDAQ:AFIB) stock lost 24.6% and on December 2nd it had a closing price of $28.20. Here is what Baron Discovery Fund said:

“We also added to our stable of high-quality medical device investments. Acutus Medical, Inc. offers an imaging platform to assist in treating arrhythmia (which is a problem with a patient’s heart in which it can beat irregularly). A complex form of arrhythmia is atrial fibrillation which is a rapid heart rate caused by chaotic electrical impulses in the atria (the upper chambers of the heart). In some cases when medication or other treatments don’t work, a patient will undergo a surgical procedure to treat the arrhythmia. Typically, this is some type of catheter-based ablation, where a thin tube with a special tip is threaded through a patient’s blood vessels from the groin to the heart. The tip of the catheter can deliver radiofrequency (heat) or cryogenic (cold) energy to particular areas of the heart muscle in order to restore a more regular rhythm. While many cases are solved by ablating a similar area of tissue, many times the first procedure doesn’t get to the right area and the surgery fails. Acutus’ AcQMap product is a catheter-delivered basket with 48 ultrasound transducers and 48 electrodes that can rapidly create a 3D map of the electrical energy moving through the heart. It does this without requiring contact with the tissue (which other competitive products need). AcQMap improves mapping speed relative to legacy systems and enables higher resolution to catch these more complex electrical patterns and deliver ablation energy to where it is needed. We believe that Acutus is in the very early stages of launching a unique product into a significant addressable market, with an estimated $5.7 billion opportunity from annual ablation procedure consumables.”

Countries with the Lowest Cancer Rates in the World in 2018


Our calculations showed that Acutus Medical Inc. (NASDAQ:AFIB) isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 216% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 121 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:

Disclosure: None. This article is originally published at Insider Monkey.